Aadi Bioscience, Inc. ("Aadi") (Nasdaq: AADI) today announced the closing of its previously announced merger with Aerpio Pharmaceuticals, Inc. (previously traded on the Nasdaq Capital Market under "ARPO").
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced dosing of the first patient with razuprotafib in the I-SPY COVID Trial (NCT04488081), a phase 2 platform trial aimed at improving treatment of acute ...
Aerpio Pharmaceuticals and Quantum Leap Healthcare Collaborative™ announced an agreement has been reached to evaluate razuprotafib in a new randomized ...
Aerpio Pharmaceuticals announced the completion of patient dosing in the company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate....